ANIK

Business Context and Reporting Period

Anika Therapeutics, Inc. (ANIK) is a global joint preservation company specializing in hyaluronic acid (HA) technology for osteoarthritis pain management, regenerative solutions, and sports medicine. This Form 10-Q covers the quarterly period ended September 30, 2024. The company recently completed a strategic review, resulting in the sale of its Arthrosurface business on October 31, 2024, and an announced intention to divest the Parcus Medical business to focus on core HA technology.

Key Financial Metrics

Liquidity and Debt: As of September 30, 2024, the company held $62.4 million in cash and cash equivalents. There were no outstanding borrowings under its $75.0 million revolving credit facility. Working capital totaled $110.6 million.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 7% in Q3 and 2% YTD compared to the prior year. This was driven by unfavorable timing of strategic partner orders in OA Pain Management and lower sales of legacy Arthrosurface and sports medicine products.
• Significant Impairment Charges: The company recorded a $27.4 million total impairment charge in Q3 2024 related to the Arthrosurface business. This included a $22.7 million inventory write-down and a $3.1 million long-lived asset impairment charge, drastically reducing gross margin to 4% for the quarter.
• Operating Expenses: SG&A expenses decreased 23% in Q3 and 20% YTD, primarily due to the absence of a $3.3 million arbitration settlement payment made in 2023, headcount reductions, and lower shareholder activism costs.
• Share Repurchases: The company repurchased 205,404 shares for $5.3 million YTD under a $40.0 million program authorized in May 2024.

Guidance, Outlook, and Risks

• Strategic Divestitures: The sale of Arthrosurface was completed on October 31, 2024, for a $7.0 million promissory note plus potential future revenue payments. The company intends to divest Parcus Medical to maximize shareholder value by focusing on core HA and regenerative products.
• Product Pipeline: Management is actively engaging with the FDA regarding U.S. approval for Cingal (OA pain management) and Hyalofast (regenerative solutions). The company acquired an NDA for Aristospan in September 2024 to assist with Cingal's regulatory filing.
• Non-GAAP Performance: Adjusted EBITDA for the nine months ended September 30, 2024, was $14.2 million, an increase of $4.5 million from the prior year, driven by lower operating expenses despite revenue declines.
• Risks: Key risks include the impact of global conflicts (Ukraine, Middle East) on supply chains and raw material costs, the outcome of the Italian tax authority examination of the 2021 tax return, and the successful commercialization of new products like Cingal in the U.S.

Investor Verification Checklist

• Arthrosurface Sale Terms: Verify the final consideration received and the structure of future revenue payments from the Arthrosurface divestiture.
• Inventory Valuation: Confirm the remaining inventory levels and reserves post-write-down to ensure no further impairments are necessary.
• Cingal Regulatory Status: Monitor FDA communication timelines and the status of the NDA filing for Cingal in the U.S. market.
• Parcus Medical Divestiture: Track the progress of the announced intention to divest the Parcus Medical business.
• Cash Burn vs. Runway: Assess the sustainability of the current cash position ($62.4 million) against operating losses and capital expenditure plans, particularly given the cessation of revenue from the Arthrosurface segment.